Hosted on MSN25d
TACE + Lenvatinib, Pembrolizumab Tied to Improved Survival in Unresectable Liver CancerThe researchers found that median progression-free survival was 14.6 and 10.0 months for TACE with lenvatinib plus pembrolizumab and TACE plus placebo, respectively (hazard ratio, 0.66 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback